GlobeNewswire Inc.··NaBeam Therapeutics Secures $500M Credit Facility to Fund Sickle Cell Therapy Launch
Beam Therapeutics secures $500M credit facility from Sixth Street Partners to fund commercial launch of its sickle cell therapy, with payments tied to clinical and regulatory milestones.
BEAMcommercializationsickle cell disease